<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> (GLP)-1 agonists and dipeptidyl peptidase-4 inhibitors are two classes of drugs that have been approved for treatment of Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, based upon the <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering actions of the gastrointestinal hormone GLP-1 </plain></SENT>
<SENT sid="1" pm="."><plain>However, GLP-1 receptors are also present in cardiovascular tissues </plain></SENT>
<SENT sid="2" pm="."><plain>Data from animal and in vitro studies suggest that GLP-1 may have cardioprotective effects and improve myocardial and <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical data demonstrating cardiovascular effects are more limited, and there is some evidence that incretin-based therapies may be associated with improvements in <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Large prospective cardiovascular outcome trials are underway to examine the cardiovascular safety of incretin-based therapies, and may reveal whether these agents are associated with any reduction in cardiovascular adverse events in patients with Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>